{
  "schema_version": 1,
  "kind": "drug_profile",
  "generic": "nystatin",
  "review_status": "reviewed",
  "origin": "openfda",
  "sections": {
    "adult": [
      {
        "text": "Very moist lesions are best treated with the topical dusting powder. Adults and Pediatric Patients (Neonates and Older) Apply to candidal lesions two or three times daily until healing is complete. For fungal infection of the feet caused by Candida species, the powder should be dusted on the feet, as well as, in all foot wear.",
        "source": "US FDA label for nystatin (Nyamyc), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/nystatin.json",
        "verbatim": true
      }
    ],
    "child": [
      {
        "text": "Safety and effectiveness have been established in the pediatric population from birth to 16 years. [see DOSAGE AND ADMINISTRATION ].",
        "source": "US FDA label for nystatin (Nyamyc), section 'pediatric use', retrieved 2026-08-29",
        "cached_file": "labels/nystatin.json",
        "verbatim": true
      },
      {
        "text": "Very moist lesions are best treated with the topical dusting powder. Adults and Pediatric Patients (Neonates and Older) Apply to candidal lesions two or three times daily until healing is complete. For fungal infection of the feet caused by Candida species, the powder should be dusted on the feet, as well as, in all foot wear.",
        "source": "US FDA label for nystatin (Nyamyc), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/nystatin.json",
        "verbatim": true
      }
    ],
    "renal": [
      {
        "text": "No kidney-impairment dose in this label. Not a statement that none is needed.",
        "source": "Read and found silent: the US FDA label for nystatin (Nyamyc), retrieved 2026-08-29",
        "cached_file": "labels/nystatin.json",
        "verbatim": false
      }
    ],
    "hepatic": [
      {
        "text": "No liver-impairment dose in this label. Not a statement that none is needed.",
        "source": "Read and found silent: the US FDA label for nystatin (Nyamyc), retrieved 2026-08-29",
        "cached_file": "labels/nystatin.json",
        "verbatim": false
      }
    ],
    "pregnancy": [
      {
        "text": "Teratogenic Effects Animal reproduction studies have not been conducted with any nystatin topical preparation.",
        "source": "US FDA label for nystatin (Nyamyc), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/nystatin.json",
        "verbatim": true
      },
      {
        "text": "It also is not known whether theses preparations can cause fetal harm when used by a pregnant woman or can affect reproductive capacity.",
        "source": "US FDA label for nystatin (Nyamyc), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/nystatin.json",
        "verbatim": true
      },
      {
        "text": "Nyamyc® (Nystatin Topical Powder, USP) should be prescribed for a pregnant woman only if the potential benefit to the mother outweighs the potential risk to the fetus.",
        "source": "US FDA label for nystatin (Nyamyc), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/nystatin.json",
        "verbatim": true
      }
    ],
    "lactation": [
      {
        "text": "It is not known whether nystatin is excreted in human milk.",
        "source": "US FDA label for nystatin (Nyamyc), section 'nursing mothers', retrieved 2026-08-29",
        "cached_file": "labels/nystatin.json",
        "verbatim": true
      },
      {
        "text": "Caution should be exercised when nystatin is prescribed for a nursing woman.",
        "source": "US FDA label for nystatin (Nyamyc), section 'nursing mothers', retrieved 2026-08-29",
        "cached_file": "labels/nystatin.json",
        "verbatim": true
      }
    ]
  }
}